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INTRODUCTION
The role of calcium – the main component of the bone 
mass – in prevention and treatment of osteoporosis has 
been extensively studied [1-8]. The recommendations 
on advised calcium (Ca) intake are generally available, 
with the tendency of dose increasing in comparison 
to the previous decades with limitation of the upper 
cutoff value in order to prevent adverse events [3, 4]. 
The results suggest positive effect of calcium supple-
mentation on the skeletal growth and peak bone mass 
in prepubertal girls, particularly those with previ-
ously low calcium intake [5]. Calcium and vitamin 
D supplementations are significant in prevention of 
early postmenopausal bone mass loss [6].
However, in spite of the fact that calcium intake 
has been widely accepted as a risk factor for future 
fractures, the results of the studies carried out so far 
are controversial. Thus, a meta-analysis performed by 
Kanis et al has failed to demonstrate the association 
between low calcium intake (less than 1 cup of milk 
per day) and a significant increase of risk from osteo-
porotic fractures in later life [7]. In the light of great 
economic burden related to osteoporotic fractures and 
having in mind low costs of combined vitamin D and 
calcium supplementation, it appears to be justifiable 
from the economic point of view [8].
Calcium supplements are available in numerous 
forms, most commonly as calcium citrate and calcium 
carbonate (CaCO3). Molluscs Pinctada maxima may 
serve as a good source of natural bio-calcium intended 
for supplementation. Emerging of pearl shell nurs-
eries in a number of countries in the world has made 
them commercially available for wide use at a rela-
tively low cost [9].
The low level of pearl powder absorption has 
always been problematic since the special structure 
of the pearls makes the release of the nutrients from 
the pearls difficult. The problem has been overcame 
by a novel, unique technology developed by pharma-
ceutical companies (Physical Ultra Fine Technology 
– PUFT), which enabled disintegration of the pearl 
powder to nanomolar pearl particles (Nanometer 
Pearl Powder – NPP). Manufacture of capsules with 
fine pulverized pearls of 40-80 nm in diameter has 
enabled 100% preservation of natural ingredients 
of the pearl powder with an enormous increase of 
pearl powder’s specific surface area (SSA), which has 
improved significantly bioavailability of the prepara-
tion with bioactive calcium absorption of 90-95%.
SUMMARY
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OBJECTIVE
The paper is aimed at monitoring of efficacy and toler-
ance of six-month bio-calcium supplementation in post-
menopausal women with reduced bone mineral density.
METHODS
The prospective study included 50 female outpatients 
treated at the Institute of Rheumatology in Belgrade, Serbia 
diagnosed with reduced spinal or hip bone density (osteo-
penia or osteoporosis). Bone mineral density (BMD) is 
measured on the lumbar spine (L) or hip according to the 
DXA method (Double Energy X-ray Absorption) using 
the Lunar DPX device.
The inclusion criteria were the following: female sex, 
menopausal status (either natural or artificially-induced 
menopause), T index of the measured region with standard 
deviation (SD) from -1 to -3, patients previously untreated 
with other therapeutic approaches for osteoporosis (antire-
sorptive and/or substitution). The study also included the 
patients in whom other specific osteoporosis treatments 
were indicated. However, they refused to comply with them.
Exclusion criteria included all forms of secondary osteo-
porosis, high risk of development of fractures, administra-
tion of drugs with adverse effects on bone density (diuretics, 
anticonvulsives, heparin, corticosteroids), severe infec-
tions, malignant diseases or other conditions rendering 
the patients unsuitable for treatment based on the inves-
tigator’s judgment.
Randomization of patients was made by drawing of 
numbers from 1-50, with patients identified with numbers 
from 1-30 allocated to a group to be subjected to substi-
tution therapy with pearl calcium Biser® (Zhejiang Fenix 
Pharmaceutical Co, Ltd. PR of China), 3×1 capsule per day, 
corresponding to 260 mg of elemental bio-CaCO3 per day. 
Biser® 250 mg capsules were granted marketing authori-
zation for the territory of Serbia by Sanitary Inspectorate 
of the Republic of Serbia. The capsules were analysed at 
the School of Pharmacy, University of Belgrade (Institute 
of Bromatology).
The second group of patients identified with numbers 
31-50 (20 patients) was supplemented with inorganic Kalcijum 
karbonat® (Alkaloid, Skopje) 1.250 mg once a day (500 mg 
of elemental calcium). Both groups were administered 666 
IU of cholecalciferol per day (Vigantol®, Merck). The study 
was approved by the Ethics Committee of the Institute of 
Rheumatology in Belgrade. All the patients were properly 
informed and gave their informed consents for inclusion 
into the study before application of any medical procedures.
Before the commencement of supplementation, labora-
tory tests were performed including serum calcium, phos-
phorus and alkaline phosphatase and 24-h urine calcium 
and phosphorus according to the spectrophotometric 
method using biochemical analyzers. After completion 
of six-month supplementation of calcium and vitamin 
D3, the DXA examination of the same skeletal region was 
performed by the same investigator and follow-up labo-
ratory tests of the same parameters as at the baseline were 
performed. Tolerance of supplementation and onset of 
adverse events were monitored.
The prospective follow-up lasted for 6 months and the 
study was carried out in the period early November 2006 
– end of December 2007.
Basic descriptive statistical methods were used (mean 
value, standard deviation, range of values, median). The 
significance of the obtained results was analysed by the 
Student’s t-test for dependent samples, where the differ-
ence was considered to be significant at p<0.05.
RESULTS
Characteristics according to groups before initiation 
of supplementation
Group I patients (n=30) were aged 61.7 (45-78) at the 
average. The menopause started at the age of 48.3 (36-55) 
and lasted for 13 (1-27) years. Previous bone fractures were 
not evidenced in 23 (76.7%) patients, while previous frac-
tures were recorded in 7 (23.3%) patients: Colles’ fractures 
of the radius in 3 patients, lumbar vertebral fractures in 1 
patient, rib and metatarsal bone fractures in one patient 
each. The average body mass was 67.7 (51-92) kg, average 
height 159.8 (147-173) cm. In majority of the patients 
(26/86.7%) BMD was measured in the lumbar spine, while 
in 4 (13.3%), it was measured in the hip. The average bone 
mineral density before supplementation was 0.901 (range 
0.736-1.033) g/cm2, with T index being -1.90 (range -3 to 
-1.2) SD (Table 1).
The average serum calcium value was 2.3 (2.0-2.62) 
mmol/l, phosphorus 1.2 (0.8-1.5) mmol/l, and alkaline 
phosphatase 68.6 (39-100) IU/l. The average calciuria in 
24-h urine was 0.18 (0.02-0.43) g/24 h, while phosphaturia 
was 0.59 (0.1-1.2) g/24 h (Table 2).
The average age of Group II patients (n=20) was the 
same - 61.7 (46-76) years. The menopause commenced in 
Table 1. General patients’ indicators
Parameters Group I Group II p
Age (years) 61.7±8.3 (45-78) 61.7±8.6 (46-76) 0.5
Onset of menopause (years) 48.3±3.9 (36-55) 48±3.3 (42-54) 0.38
Duration of menopause (years) 13.4±7.3 (1-27) 13.7±9.5 (2-33) 0.447
Fractures (number)
No 23 (76.7%) 15 (75%)
Yes 7 (23.3%) 5 (25%)
Body weight (kg) 67.7±10.3 (51-92) 71.1±9.7 (52-90) 0.140
Body height (cm) 159.8±6.2 (147-173) 162.2±3.4 (157-169) 0.08
Body mass index (kg/m2) 27.2±3.2 (21.9-33) 26.9±4.1(19.3-32.3) 0.289520 СРПСКИ АРХИВ ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
this group at the age of 48 (42-54) and lasted 13.7 (2-33) 
years. Majority of the patients (15/75%) were free of bone 
fractures, while previous bone fractures were present in 5 
(25%) patients: radius and lower leg fracture in the first one, 
lumbar vertebral fracture in the second, two fractures of 
the radius in the third, radius fracture in the fourth, while 
multiple fractures were evidenced in the fifth patient. Their 
average body mass was 71 (52-90) kg, height 162 (157-169) 
cm, and BMI 27 (19.3- 32.3) kg/m2 (Table 1).
In 16 (80%) patients, BMD was measured on the lumbar 
spine, while in 4 (20%), it was measured on the hip. The 
average bone density was 0.913 (0.632-1.03) g/cm2, while 
T index was -1.90 (from -3 to -1.32) SD (Table 3).
The average blood calcium value was 2.3 (2.0-2.8) mmol/l, 
phosphorus 1.2 (range 0.9 - 1.7) mmol/l, alkaline phospha-
tase approximately 69 (29.4-107) IU. The average calciuria 
measured in 24-h urine was 0.21 (0.04-0.5) g/24 h, with 
phosphaturia being 0.65 (range 0.3 -1.3) g/24 h (Table 2).
None of the observed parameters (age, onset and duration 
of menopause, body mass, height, BMI, BMD and T-score 
values or laboratory indicators) did not differ significantly 
between the two groups before supplementation.
Results after six-month supplementation
Out of 30 patients of group I, six-month supplementation 
was completed in 27 patients. Based on the physician’s deci-
sion, 2 patients were excluded: one due to scheduled gastro-
intestinal investigations, and the other for non-compli-
ance with Ca/vitamin D3 schedule. The third patient left 
the study based on her own decision. None of the patients 
lost for further follow-up reported adverse events in the 
course of supplementation (Table 4).
BMD increase in the measured region from 0.901 to 0.948 
g/cm2 was evidenced in this group, which is close to the 
significance limit (p=0.067), as well as reduced negativity 
of T index from -1.9 to -1.7 (p=0.179) (Table 3, Graph 1).
Mean blood values of calcium 2.4 (2.2-2.4), phosphorus 
1.2 (0.88-1.67) and alkaline phosphates 64.2 (46.9-84.5) 
did not differ significantly in comparison to the base-
line values. Moreover, no significant changes in calci-
uria (0.26) and phosphaturia (0.62) in 24-h urine were 
detected (Table 2).
Good tolerance of pearl calcium was recorded in all 27 
patients who completed six-month follow-up. In the course 
of a six-month follow-up, one of the patients (3.7%) reported 
an adverse event manifested as increase of body weight 
(Table 4). No new fractures were evidenced in this period.
A six-month treatment was completed in 17 out of 20 
included patients of group II. One of the patients left the 
Table 4. Tolerance and adverse events by the end and during six-
month treatment
Parameters Group I Group II
Tolerance after 6 
months
Good 27/27 (100%) 14/17 (82.3%)
Poor - 3/17 (17.6%)
Adverse events 0-6 
months
Absent 29/30 (97%) 15/20 (75%)
Present 1/30 (3.3)* 5/20 (25%)**
* One patient reported weight gain
** Two patients reported dyspepsia: nausea, bloating, abdominal pain; one 
reported rapid heart beats; other two patients discontinued treatment due 
to adverse events
Table 2. Laboratory parameters according to groups before and af-
ter six-month supplementation
Parameters Group I Group II p
Serum calcium
Before 2.3±0.16 2.3±0.18
0.292
After 2.3±0.12* 2.3±0.13**
Serum 
phosphorus
Before 1.2±0.2 1.2±0.17
0.470
After 1.2±0.19* 1.2±0.08**
Alkaline 
phosphatase
Before 68.6±15.2 69.1±18.9
0.461
After 64.2±11.9* 60.7±21.3**
Urine calcium
Before 0.18±0.1 0.21±0.15
0.218
After 0.26±0.3* 0.28±0.2
Urine phosphorus
Before 0.59±0.3 0.65±0.36
0.201
After 0.62±0.2* 0.58±0.29**
* 3 patients lost for follow-up;
**3 patients lost for follow-up; 1 patient refused blood taking, urine analyses 
were performed
Laboratory test changes after 6 months in comparison to baseline values:
Group I: serum Ca p=0.219; serum P p=0.467; alkaline phosphatase p=0.235; 
urine Ca p=0.168; urine P p=0.796;
Group II: serum Ca p=0.702; serum P p=0.909; alkaline phosphatase p=0.458; 
urine Ca p=1.3; urine phosphorus p=0.408
Table 3. Bone mineral density according to groups
Parameters Group I Group II p
DXA (number)
Lumbar spine 26 (86.7% ) 16 (80%)
Hip 4 (13.3%) 4 (20%)
BMD (g/cm2)
Before supplementation 0.901±0.088 (0.74-1.03) 0.913±0.101 (0.63-1.03) p=0.332§
After 6 months 0.948±0.109 (0.68-1.11)* 0.914±0.128 (0.69-1.04)#
T-score (SD)
Before supplementation -1.9±0.42 (-3 to -1.2) -1.9±0.72(3.1 to -1.32) p=0.303§
After 6 months -1.7±0.481 (-3 to -1.1)** -1.9±0.72 (-3.1 to -1.32)##
* BMD before and after 6-month treatment p=0.067; ** T-score before and after 6-month treatment t test p=0.179;
# BMD before and after treatment p=0.987; ## T-score before and after treatment p=0.725; § between the groups before commencement of treatment
Graph 1. Bone mineral density before and after 6-month supple-
mentation
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study based on her own decision, while the other 2 were 
excluded due to the onset of adverse events. The first patient 
was excluded 10 days after the commencement of supple-
mentation due to gastric pains, nausea and vomiting while 
the second was excluded after 3 months since she reported 
vitamin D intolerance (persistent diarrhoeas following each 
administration of the drops) (Table 4).
An increase of bone mineral density was practically 
not recorded in this group (BMD at baseline 0.913, by the 
end of follow-up 0.914; p=0.987) or T-score change (-1.9 
at baseline and at the end of follow-up) (Table 3, Graph 1).
Significant changes of laboratory and urine blood param-
eters were not recorded in this group either. Mean value 
of blood calcium was 2.3 (2.1-2.43) mmol/l, phosphorus 
1.2 (1.1-1.3) mmol/l and alkaline phosphatase 60.7 (45.7-
74.8) IU. Moreover, calciuria increase from 0.21 to 0.28 
g/24 h was not statistically significant or decrease of phos-
phaturia value in g/24 h (Table 2).
Good tolerance was recorded in 14 out of 17 patients 
who completed six-month supplementation. Lack of toler-
ance in the form of nausea, bloating and gastric pains was 
reported by 2 patients, while the third one reported rapid 
heart beats. With 2 patients withdrawn from the study when 
adverse events are taken into account, the total number of 
patients who developed adverse events over the 6-month 
follow-up was 5 out of 20 (25%) patients (Table 4). No new 
fractures were recorded in this group either.
DISCUSSION
The long-term process of treatment of osteoporosis necessi-
tates, in addition to specific antiresorptive therapy, calcium 
and vitamin D supplementation. Investigators from Denmark 
reported, in ~10,000 individuals aged ≥66, living indepen-
dently, significant (16%, p<0.025) reduction of risk frac-
tures in case of the application of calcium and vitamin D 
supplementation [10].
We are aware that assessment of efficacy after 6 months 
is a short period to achieve BMD to be documented by the 
DXA method. However, our results indicate the increase 
of bone mineral density as early as after six months after 
administration of biological CaCO3 in postmenopausal 
women with reduced bone density. No changes of bone 
density were recorded after 6-month supplementation in 
the group receiving twice as high inorganic CaCO3 dose.
Tolerance of bio-calcium supplementation was excel-
lent in absence of any adverse events with good adher-
ence to treatment. The information was highly significant, 
having in mind our own experience, and reference liter-
ature data, reporting that particularly poor compliance 
was associated with calcium/vitamin D supplementation, 
which emphasized the need for finding the new routes of 
supplementation [11].
Giant seashells Pinctada maxima, similarly to other 
members of Pinctada genus produce large pearls throughout 
their life. Both, pearl and mother-of-pearl, are basically 
composed of CaCO3 (aragonite), while the bone is mostly 
composed of calcium phosphate (hydroxyapatite, HA) [9, 
12]. The process of shell bio-mineralization has not been 
completely elucidated yet. Organic calcium mostly origi-
nates from plankton used by shells for their nourishment, 
while pearl composition depends on the composition and 
temperature of seawater [13]. Initially formed meshwork 
of the organic matrix induced formation of crystals within 
the allowed space, which necessitates a continuous supply 
with calcium, with its uptake, active transport, accumu-
lation and particularly regulatory processes of the mech-
anism still being an attractive field of research [12, 13].
By far more intriguing from the mineral part of the 
pearl is the organic one, which makes 2-8% of their content 
[10]. These two pearl components are arranged in several 
hundreds of closely, alternatively related layers [9, 13]. 
Phylogenetically highly distinct mechanisms of pearl and 
bone mineralization still have a common characteristic – 
both are the products of living organism bio-mineralization. 
The studies carried out so far have indicated that the pearl 
matrix has numerous diffusible, water-soluble proteins and 
growth factors (Water-Soluble Matrix-WSM) controlling 
both in vivo and in vitro the process of pearl bio-miner-
alization based on the mechanism similar to osteogen-
esis, i.e., HA synthesis in human population [9, 13, 14]. 
Previous studies have provided solid evidence that nacre 
produced by shell Pinctada maxima may stimulate osteo-
blast culture both, in vivo and in vitro, to produce bone 
(osteogenic activity), which makes it a suitable material 
for bone reparation [9, 13, 14]. In vitro studies support 
the initial hypothesis suggesting that diffusible signaling 
molecules of the shell nacre organic matrix are included 
in stimulation of mammalian osteoblasts – targeted cells 
in the process of bone synthesis [15]. Increased activity of 
alkaline phosphatase (osteoblast differentiation marker) 
has been documented in osteoblast and WSM culture 
as well as the increased quantity of antiapoptotic proon-
cogen Bcl-2 in the osteoblast cytoplasm and nucleus. It 
has also been evidenced that calmodulin - intracellular 
calcium sensor protein – actively participates in calcium 
transport, aimed at its deposition in the matrix meshwork 
as well as that only two amino acid residues in its struc-
tures have been changed during evolution from molluscs 
to vertebrata [12, 16].
Wide dental application of the alveolar implants made 
of natural calcium carbonate (bioracine) obtained from 
shells Pinctada maxima has evidenced that the chips may 
be implanted in human bone, accepted by the human body 
to express biological response through release of the active 
molecules that induce bone regeneration. The response 
included local osteogenetic activity and nacre integration 
into the host bone in absence of inflammatory reaction. 
Histological studies have evidenced unusual cellular fusion 
of the two types of tissue on the junction between the alve-
olar implants and human maxillary bone [17].
CONCLUSION
Six-month supplementation with CaCO3 of the biological 
origin in the daily dose of 260 mg has led to the increase 
of bone mineral density from 0.901 g/cm2 to 0.948 g/cm2 
(p=0.067), while bone mineral density remained the same 522 СРПСКИ АРХИВ ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
in the group supplemented with inorganic CaCO3 in the 
daily dose of 500 mg. However, these data could not strongly 
support the hypothesis of better efficacy of bio-calcium 
taking into account a small number of patients and a short 
follow-up period in this pilot study.
Tolerance of CaCO3 of the biological origin was excel-
lent and free of any adverse events.
The results of laboratory calcium, phosphorus and alka-
line phosphatase blood tests as well as calcium and phos-
phorus urine levels were within normal cutoff values.
NOTE
The results of this paper were presented as oral or poster 
presentation at: Meeting of the Physicians of Vojvodina, 
Kanjiza Spa 27/3/2008; 27th Timok’s Medical Days, Zajecar, 
May 22-24, 2008; The Annual Meeting of Rheumatologists 
of the Republic of Serbia, Ivanjica, September 26, 2008; 
ICOBR 2008 - International Conference on Osteoporosis 
and Bone Research 2008, China, Beijing, October 22-25, 
2008. Abstract has been published in Bone 2008; 43(Suppl 
1):A67.
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KRATAK SADRŽAJ
Uvod  Le  če we  oste o po ro ze,  uz  spe ci fič n u   a n  t i  r e  s o r p  t i v  n u  
ili ana bo lič ku te ra pi ju, zah te va su ple men ta ci ju kal ci ju mom 
i   v i  t a  m i  n o m   D .   Gl a v  n i   s a  s t o  j a k   b i  s e  r a   š k o q  k e   Pin cta da  ma xi-
ma  je  kal ci jum-kar bo nat  (Ca CO3) .   Te h  n o  l o  g i  j o m   m i  k r o  n i  z a  c i -
j e   b i  s e  r a   u   n a  n o  m o  l a r  n i   p r a h   p o  v e  ća  n a   j e   g a  s t r o  i n  t e  s t i  n a l -
n a   a p  s o r p  c i  j a   k a l  c i  j u  m a   d o   v i  š e   o d   9 0 %   u z e  t e   d o  z e .   Ku l  t i  v a -
ci  ja bi  ser  nih škoq  ki ih je uči ni la  op šte  do stup nim  po  vr-
lo  pri stu pač noj  ce ni.
Ciq ra  da  Ciq is  tra  ži  va  wa je bio da se usta  no  ve efi  ka-
s n o s t   i   p o d  n o  š q i  v o s t   s u  p l e  m e n  t a  c i  j e   b i  o  l o  š k i m   k a l  c i  j u -
mom  kod  že na  u  post me no pa u zi  sa  sma we nom  mi ne ral nom  gu-
sti nom  ko sti  (engl.  bo ne mi ne ral den sity – BMD).
M e  t o  d e  r a  d a   Me  re  ni su BMD kič me  ili  ku ka  i  kon cen tra ci-
je  al kal ne  fos fa ta ze,  kal ci ju ma  i  fos fo ra  u  se ru mu  i  24-ča-
sov nom uri nu pre i šest me se ci po sle su ple men ta ci je. Is pi-
ta  ni  ce su svr  sta  ne u dve gru  pe: pr  vu je či ni lo  30  že na  ko je  su 
pri ma le  su ple men ta ci ju  Ca CO3  u  vi du  kap su la  bi ser nog  pra-
ha škoq  ki Pin cta da  ma xi ma  (od go va ra  260  mg  ele men tar nog 
kal ci ju ma),  a  dru gu  gru pu  20  že na  ko je  su  pri ma le  neo r gan ski 
Ca CO3 (500 mg  ele men tar nog  kal ci ju ma).  Obe  gru pe  su  pri ma-
l e   i s t u   d n e v  n u   d o  z u   h o  l e  k a l  c i  f e  r o  l a   (6 6 6   I J ) .
Re zul ta ti  Pro  seč n a   s t a  r o s t   i s  p i  t a  n i  c a   d v e   g r u  p e   b i  l a   j e  
ista – 61,7 go  di  na. Na po  če t  k u   m e  n o  p a  u  z e   i s  p i  t a  n i  c e   p r  v e  
g r u  p e   s u   u   p r o  s e  k u   i m a  l e   4 8 , 3   g o  d i  n e ,   a   i s  p i  t a  n i  c e   d r u  g e   g r u -
p e   4 8   g o  d i  n a .   M e  n o  p a  u  z a   j e   u   p r o  s e  k u   t r a  j a  l a   13 , 4   g o  d i  n e   k o d  
i s  p i  t a  n i  c a   p r  v e   g r u  p e ,   a   13 , 7   g o  d i  n a   k o d   i s  p i  t a  n i  c a   d r u  g e  
gru pe.  Pro seč n a   v r e d  n o s t   i n  d e k  s a   t e  l e  s n e   m a  s e   u   p r  v o j   g r u  p i  
bi  la je 27,2 kg/m2, a u dru  goj 27 kg/m2. Gru  pe su se po svim pa  ra-
m e  t r i  m a   m o  g l e   p o  r e  d i  t i   ( p>0,05). BMD se kod že  na pr  ve gru-
pe na  kon šest me  se  ci po  ve  ća  la sa 0,901±0,088 na 0,948±0,109 
g/cm2 (p=0,067),  dok  u  dru goj  gru pi  ni je  za be le že na  pro me na 
BMD.  Bi o lo ški  Ca CO3  i s  p i  t a  n i  c e   s u   o d  l i č no  pod ne le  i  ni je 
b i  l o   n e  ž e  q e  n i h   r e  a k  c i  j a .
Za kqu čak    Re zul ta ti  ove  pi lot-stu di je  ne  mo gu  čvr  sto da po-
d r  ž e   h i  p o  t e  z u   o   b o  q o j   e f i  k a  s n o  s t i   s u  p l e  m e n  t a  c i  j e   b i  o  l o -
škim  kal ci ju mom  u  od no su  na  neo r gan ski,  bu du ći da je broj 
i s  p i  t a  n i  k a   b i o   m a  l i ,   a   p e  r i o d   p o  s m a  t r a  w a   k r a  t a k .   I p a k ,  
u s t a  n o  v q e  n a   j e   o d  l i č na  pod no šqi vost  Ca CO3  bi o lo škog  po-
r e  k l a ,   a   n e  ž e  q e  n i h   r e  a k  c i  j a   n i  j e   b i  l o .   S v i   l a  b o  r a  t o  r i j  s k i  
p o  k a  z a  t e  q i   u   o b e   g r u  p e   i s  p i  t a  n i  c a   b i  l i   s u   u   g r a  n i  c a  m a   n o r -
mal nih  vred no sti.
Kquč ne re či:  s u  p l e  m e n  t a  c i  j a   k a l  c i  j u  m o m ;   b i  o  l o  š k i   k a l  c i -
jum;  neo r gan ski  kal ci jum;  oste o po ro za;  Pin cta da ma xi ma
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